Compare American International Group Inc (AIG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs IDEXX Laboratories, Inc. — how do they compare? American International Group Inc trades at $76.02 (market cap $40.42B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: American International Group Inc and IDEXX Laboratories, Inc. are close in size by market cap, and American International Group Inc pays a 2.59% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| AIG | IDXX | |
|---|---|---|
Market Cap | $40.42B | $46.22B |
Sector | Financials | Health |
52-Week High | $86.59 | $766.68 |
52-Week Low | $71.89 | $526.44 |
Enterprise Value | $48.06B | $47.12B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.33, down 1.65% on the day, with a bearish technical signal and neutral oscillators. The company shows strong earnings momentum with three consecutive quarterly beats (Q4 2025: $1.96 vs $1.90 expected, Q1 2026: $2.11 vs $1.89, Q2 2026: $2.00 vs $1.92) and maintains a 11.12% net income margin. Recent news highlights CEO Eric Anderson discussing geopolitical opportunities and strong Q2 results with 10% adjusted EPS growth.
AIG presents a mixed outlook with solid fundamentals and earnings consistency offset by bearish technicals. The 12-month consensus price target of $89.00 suggests 16.6% upside potential, supported by 39% analyst buy ratings. Key risks include competitive pricing pressure in North American property insurance and market volatility. The stock's current valuation at 14.11 P/E appears reasonable given earnings growth trajectory.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
